Clinical outcomes and quality of life in patients with MPN and MDS continue to be enhanced as cytogenetic analysis and novel therapeutic strategies are incorporated into disease management regimens. Recently proposed changes to refine and strengthen diagnostic and risk-assessment models, along with the rapid evolution of disease management strategies that utilize standard of care and/or novel therapeutic agents, will likely further enhance clinical outcomes in patients with MPN and MDS and improve their quality of life.

This webcast of the 2016 European Focus on Myeloproliferative Neoplasms & Myelodysplastic Syndromes held in Zagreb, Croatia from 5-7 May 2016 addresses the most intriguing and clinically applicable topics and data, outlines key learning points, and reinforces the take-home messages regarding the treatment of MPN and MDS from the Congress.

In this presentation, Dr. Srdan Verstovsek provides an update on several JAK inhibitors in development for use in the treatment of myelofibrosis (MF).

Earn accreditation for this activity at the following location:
[ Ссылка ]

© 2016 Imedex, LLC.

свернуть